Evoke Pharma to Present at 26th Annual ROTH Conference
SAN DIEGO, March 4, 2014 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that its President and Chief Executive Officer, Dave Gonyer, R.Ph., will be presenting at the 26th Annual ROTH Conference, being held March 10-12, 2014 at the Ritz-Carlton in Dana Point, California.
Mr. Gonyer is scheduled to present on Tuesday, March 11, 2014 at 9:30 a.m. PT. The presentation will highlight the Company's novel intranasal formulation and delivery of metoclopramide (EVK-001) for treatment of symptoms of gastroparesis, results from its Phase 2b clinical trial, the upcoming Phase 3 clinical trial and the market opportunity for EVK-001.
Details of the presentation are as follows:
Date: Tuesday, March 11, 2014
Time: 9:30 a.m. PT
Place: The Ritz-Carlton, Dana Point
Track: 6 - Salon 6
About Evoke Pharma, Inc.
Evoke is a specialty pharmaceutical company focused primarily on the development of drugs to treat GI disorders and diseases. The Company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women with diabetes mellitus. Diabetic gastroparesis is a GI disorder afflicting millions of sufferers worldwide, in which the stomach takes too long to empty its contents resulting in serious digestive system symptoms. Metoclopramide is the only product currently approved in the United States to treat gastroparesis, and is currently available only in oral and intravenous forms. EVK-001 is a novel formulation of this drug, designed to provide systemic delivery of metoclopramide through intranasal administration.
Safe Harbor Statement
Evoke cautions you that statements included in this press release or the presentation at the 26th Annual ROTH Conference that are not a description of historical facts are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplates," "believes," "estimates," "predicts," "potential" or "continue" or the negatives of these terms or other similar expressions. These statements are based on the company's current beliefs and expectations. These forward-looking statements include statements regarding the upcoming Phase 3 clinical trial and the market opportunity for EVK-001. The inclusion of forward-looking statements should not be regarded as a representation by Evoke that any of its plans will be achieved. Actual
results may differ from those set forth in this press release or the presentation due to the risk and uncertainties inherent in Evoke's business, including, without limitation: the inherent risks of clinical development of EVK-001, including potential delays in enrollment and completion of clinical trials, including the planned Phase 3 trial; Evoke will require substantial additional funding, including potentially to complete the planned Phase 3 clinical trial of EVK-001 as well as finance additional development requirements, and may be unable to raise capital when needed; the potential for adverse safety findings relating to EVK-001 to delay or prevent regulatory approval or commercialization; Evoke's reliance on outsourcing arrangements for many of its activities, including clinical development and supply of EVK-001; and other risks detailed in Evoke's prior press releases and in the
periodic reports it files with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Evoke undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
CONTACT: Investor Contact:
The Ruth GroupDavid Burke
Tel: 646-536-7009
dburke@theruthgroup.com
Media Contact:
The Ruth GroupAaron Estrada
Tel: 646-536-7028
aaestrada@theruthgroup.com
Source: Evoke Pharma
News Provided by Acquire Media
